TY  - JOUR
T1  - Cellular senescence in cancer treatment: friend or foe?
A1  - Kahlem, Pascal
LA  - en
PB  - American Society for Clinical Investigation
YR  - 2004
UL  - http://buscaintegrada.pucsp.br/vufind/Record/pubmed-311442
AB  - Damage to DNA, the prime target of anticancer therapy, triggers programmed cellular responses. In addition to apoptosis, therapy-mediated premature senescence has been identified as another drug-responsive program that impacts the outcome of cancer therapy. Here, we discuss whether induction of senescence is a beneficial or, rather, a detrimental consequence of the therapeutic intervention.
KW  - Perspective Series
ER  -